Exelixis is on a Mission to Help Cancer Patients Recover Stronger and Live Longer
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model system genetics, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. Our discovery efforts have resulted in four commercially available products, CABOMETYX^® (cabozantinib), COMETRIQ^® (cabozantinib), COTELLIC^® (cobimetinib) and MINNEBRO^® (esaxerenone), and we have entered into partnerships with leading pharmaceutical companies to bring these important medicines to patients worldwide. Supported by revenues from our marketed products and collaborations, we are committed to prudently reinvesting in our business to maximize the potential of our pipeline. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery — all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis is a member of the Standard & Poor’s (S&P) MidCap 400 index, which measures the performance of profitable mid-sized companies.

The Exelixis Credo
We drive for results, so patients can survive and thrive.
We are resilient in the face of adversity, and tireless in advancing our science.
We celebrate our long history of prolific drug discovery and rigorous drug development.
We unite to launch innovative medicines for difficult-to-treat cancers.
We exist to give people hope – one drug, one patient at a time.
We are Exelixis.

Cancer is our cause. Make it yours, too.

We employ the best in biotech to discover, develop and commercialize medicines that help patients living with cancer recover stronger and live longer. Join our collective quest for oncology excellence and help us achieve our important and ambitious goals.

We’re expanding our teams company-wide in areas including Drug Discovery, Clinical Development, Commercial and Administration for our Alameda and Philadelphia locations.

Work with us in Alameda and Philadelphia!
Exelixis is headquartered in Alameda’s Waterfront at Harbor Bay in a large, modern campus with state-of-the-art lab space that provides room for continued growth. The company has also expanded East with a new location in the Philadelphia area focused on our discovery and development capabilities in addition to other business operational functions.

We’re Driven by an Ambitious Cause
At Exelixis, our focus and commitment is clear: to launch new medicines that give patients and their families hope for the future.

OUR VALUES

• Be Exceptional: Take the right action and lead others to do the right thing at the right time in the right way.
• Excel for Patients: Innovate to design solutions and remove barriers to show how much we care.
• Exceed Together: Apply rigor, resourcefulness and respect to maximize opportunities and deliver impactful results.